BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 8126587)

  • 1. Allogeneic bone marrow transplantation: experience with 92 patients.
    Selby GB; Saez RA; Epstein RB; Slease RB; Confer DL
    J Okla State Med Assoc; 1993 Dec; 86(12):599-603. PubMed ID: 8126587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colony growth in cultures from bone marrow and peripheral blood after curative treatment for leukemia and severe aplastic anemia.
    Betticher DC; Huxol H; Müller R; Speck B; Nissen C
    Exp Hematol; 1993 Nov; 21(12):1517-21. PubMed ID: 8405233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic bone marrow transplantation for children with acute leukemia: long-term follow-up of patients prepared with high-dose cytosine arabinoside and fractionated total body irradiation.
    Gordon BG; Warkentin PI; Strandjord SE; Abromowitch M; Bayever E; Harper JL; Coccia PF
    Bone Marrow Transplant; 1997 Jul; 20(1):5-10. PubMed ID: 9232249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic bone marrow transplantation for the patients with hemopoietic stem cell disorders: CUMC experience.
    Kim DJ; Kim CC; Park CW; Han CH; Kim HK; Kim WI; Han KJ; Choi IB
    Gan To Kagaku Ryoho; 1992 Jul; 19(8 Suppl):1188-92. PubMed ID: 1514832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Innsbruck results of bone marrow transplantation in treatment of hematologic neoplasms and solid tumors].
    Nachbaur D; Schwaighofer H; Thaler J; Weyrer W; Fink M; Nussbaumer W; Fritsch E; Niederwieser D
    Wien Klin Wochenschr; 1994; 106(7):201-7. PubMed ID: 8197754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
    Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
    Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical sibling and alternative donors.
    Demuynck H; Verhoef GE; Zachee P; Emonds MP; van der Schueren E; van den Berghe H; Vandenberghe P; Casteels-Van Daele M; Boogaerts MA
    Bone Marrow Transplant; 1996 May; 17(5):745-51. PubMed ID: 8733692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiation-free regimens result in similar outcomes of allogeneic hematopoietic progenitor cell transplantation in patients aged >or=50 years compared to younger adults with low-risk disease.
    Farag SS; Elder PJ; Marcucci G; Penza S; Mrozek E; Molina A; Lin T; Avalos BR; Copelan E
    Bone Marrow Transplant; 2003 Jan; 31(2):87-93. PubMed ID: 12621488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Indications, technique and risks in bone marrow transplantation in adulthood].
    Heyll A; Söhngen D; Minning H; Meckenstock G; Aul C; Schneider W
    Praxis (Bern 1994); 1996 Mar; 85(12):378-86. PubMed ID: 8643901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Runde V; de Witte T; Arnold R; Gratwohl A; Hermans J; van Biezen A; Niederwieser D; Labopin M; Walter-Noel MP; Bacigalupo A; Jacobsen N; Ljungman P; Carreras E; Kolb HJ; Aul C; Apperley J
    Bone Marrow Transplant; 1998 Feb; 21(3):255-61. PubMed ID: 9489648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
    Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R
    Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome.
    Shiobara S; Nakao S; Ueda M; Yamazaki H; Takahashi S; Asano S; Yabe H; Kato S; Imoto S; Maruta A; Yoshida T; Gondo H; Morishima Y; Kodera Y
    Bone Marrow Transplant; 2000 Oct; 26(7):769-74. PubMed ID: 11042659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic bone marrow transplantation in Korea: 1983-92.
    Kim DJ; Kim CC; Kim BK; Kim DW; Lee JW; Jin JY; Han CW; Min WS; Park CW; Kim HK
    Bone Marrow Transplant; 1994 Jun; 13(6):717-9. PubMed ID: 7920301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relapsed acute lymphoblastic leukemia: similar outcomes for autologous and allogeneic marrow transplantation in selected children.
    Parsons SK; Castellino SM; Lehmann LE; Eickhoff CE; Tarbell NJ; Sallan SE; Weinstein HJ; Billett AL
    Bone Marrow Transplant; 1996 May; 17(5):763-8. PubMed ID: 8733695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation.
    Wong R; Shahjahan M; Wang X; Thall PF; De Lima M; Khouri I; Gajewski J; Alamo J; Couriel D; Andersson BS; Donato M; Hosing C; Komanduri K; Anderlini P; Molldrem J; Ueno NT; Estey E; Ippoliti C; Champlin R; Giralt S
    Biol Blood Marrow Transplant; 2005 Feb; 11(2):108-14. PubMed ID: 15682071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Induction of aGVHD after allogeneic hematopoietic stem cell transplantation for refractory or relapsed acute leukemia].
    Sun J; Meng FY; Liu QF; Xu D; Xu B; Liu XL
    Ai Zheng; 2003 Dec; 22(12):1321-4. PubMed ID: 14693060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogenic bone marrow transplantation for leukemias and aplastic anemia.
    Tsai TW; Freytes CO
    Adv Intern Med; 1997; 42():423-51. PubMed ID: 9048126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.